Cold FX (150 Capsules)

Retail Price:
Our Price:

US$61.99
US$62.16

Our top selling product! Seen on news casts across USA. A favorite here in our office. COLD-FX contains 200 mg of a concentrate of immuno-boosters, high in oligosaccharides, extracted from North American Ginseng (Panax quinquefolium). Studies show that COLD-FX is a potent immune stiumlant, unlike any other. The advantages of choosing COLD-FX is its immediate bioavailablility, its rapid absorbtion rate, its predictable, consistent response, and its reputation for maintaining good health. Seven Clinical Studies totaling 641 participants have shown the product to be safe and effective including a successful US FDA randomized double-blind placebo-controlled trial. COLD-fX® prevents recurrent cold and flu infections by 56% and significantly reduces days of illness and symptom severity. A Health Canada authorized randomized, double-blind, placebo-controlled trial was conducted on 279 healthy adults from the general population (18-65 years of age) with a history of at least two upper respiratory infections (colds) in the previous year. COLD-fX (2 X 200 mg/day) taken for four months was shown to significantly reduce (26%) the average number and frequency of upper respiratory infections per person versus the placebo group. The incidence of recurrent infections was reduced by 56%. A reduction in the total number of days suffered with cold or flu symptoms from 10.9 to 6.0, and a 31% reduction in the severity of symptoms, was also observed with COLD-fX treatment. COLD-fX was shown to significantly stimulate the total number of T-lymphocytes and T-helper lymphocytes, as well as Natural Killer (NK) cells. The safety analysis indicated that COLD-fX was safe and well-tolerated. COLD-fX® reduces risk of colds, flu and respiratory illness by 89%. A US FDA authorized randomized double-blind, placebo-controlled trial of COLD-fX® (CVT-E002), in institutionalized older adults, demonstrated COLD-fX® significantly reduced the risk, by 89%, of developing laboratory confirmed influenza or respiratory syncytial virus (RSV) in a senior population after 8-12 weeks of treatment. At a dose of 400 mg daily (2 X 200 mg), COLD-fX® was shown to be safe, well tolerated, and effective for preventing acute respiratory illness due to influenza and RSV. This trial also demonstrated COLD-fX is safe and complimentary to the flu vaccine. A double-blind, placebo controlled study of COLD-fX® in an immunocompetent community dwelling of adults aged 65 years or older demonstrated a statistically significant reduction in the number of illnesses, the majority of which were associated with respiratory symptoms. The significant results included a greater incidence of respiratory symptoms in the placebo group, 76%, versus 45% in COLD-fX® group after 4 months of treatment at 400mg (2 X 200mg) daily. COLD-fX® was shown to be safe and well tolerated

Sizes

150 Capsules

Manufacturer

CV Technologies

Directions

For health maintenance: 1-2 capsules daily. For short term use: Day 1: 3 capsules 3 times a day, Day 2: 2 capsules 3 times a day, Day 3: 1 capsule 3 times a day.

Ingredients

200mg CVT-E002 from North American Ginseng.

Cautions

People with serious health conditions of taking other medications, or pregnant or lactating women, should consult a health care professional before taking Cold FX. As a derivative of North American ginseng, it is not recommended for people with allergies to ginseng. Do not exceed the recommended daily dose.

Item Number

mckesson